Welcome to Sanodyne Therapeutics Healing Lives, Relieving Pain
At Sanodyne Therapeutics, we are dedicated to bringing hope and relief to patients suffering from peripheral neuropathy and neuropathic pain. By leveraging cutting-edge science and our deep experience in pain management, We are committed to developing innovative therapies that restore comfort and improve quality of life.
About Us
Our Name Reflects Our Mission: Sano (Healing) + Anodyne (Pain Relief) = Sanodyne
Sanodyne Therapeutics is a Japan-based biotech company focused on discovering and developing novel therapeutics for patients living with chronic pain, particularly peripheral neuropathy.
Our Mission
To create breakthrough treatments that go beyond symptom control and address the underlying causes of peripheral neuropathy, bringing true relief and healing to patients worldwide.
Our Lead Program: SNT-001
A First-in-Class Therapy for Peripheral Neuropathy
SNT-001 is a novel, orally available, peripherally acting compound with a unique mechanism of action offering the potential for disease-modifying effects by promoting nerve repair.
After successfully completing Phase 1 clinical trials (including both Caucasian and Japanese cohorts), SNT-001 is now ready to enter Phase 2 clinical development. This next phase will target unmet medical needs in patients with peripheral neuropathy
Our Team
Leadership
Kazuhiko Nonomura, Ph.D. – Representative Director
Takuma Tsuzuku – Director
